Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00133445
Other study ID # 03-062
Secondary ID
Status Completed
Phase Phase 2
First received August 19, 2005
Last updated November 3, 2011
Start date December 2005
Est. completion date August 2006

Study information

Verified date October 2009
Source National Institute of Allergy and Infectious Diseases (NIAID)
Contact n/a
Is FDA regulated No
Health authority United States: Federal GovernmentUnited States: Food and Drug AdministrationUnited States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety of administering a combination vaccine (DTaP-HepB-IPV; Pediarix™) to infants at birth, 2 and 6 months compared to the administration of a HepB vaccine at birth and the same combination vaccine at 2, 4, and 6 months of age. Additionally, researchers will assess the body's antibody response (proteins produced by the body's immune system that help fight infections) following each vaccine dose. The study will enroll 5 healthy newborns, ages 0-5 days. Participants will be involved in study related procedures for up to 288 days, including blood sample collection and 5 study visits.


Description:

Routine immunization at birth is standard for hepatitis B in the United States (US) and for hepatitis B, polio and tuberculosis (BCG) in many countries. Other vaccines have not been routinely administered at birth largely due to concerns relating to immaturity of the neonatal immune system and the possibility of reduced immune response to vaccine antigens. With the recent licensure in the US of a pentavalent combination vaccine (DTaP-Hep B-IPV; Pediarix™) researchers propose to evaluate a new immunization schedule that includes a birth dose of this vaccine, in an effort to determine adequacy of neonatal immune response to the study vaccine antigens. The primary objectives of this study are: to evaluate the safety of administering the pentavalent combination vaccine (DTaP-HepB-IPV; Pediarix™) to infants at birth, two and six months of age compared to the administration of a hepatitis B vaccine (Engerix-B) at birth and the same pentavalent combination vaccine at two, four and six months of age; and to assess age specific antibody response following each vaccine dose. Five healthy newborns; 0 to 5 days of age, greater than or equal to 37 weeks gestation, and greater than 2500 gm birth weight were recruited from two Southern California Kaiser Permanente medical centers. Infants were randomized to one of 2 study groups: Group A received DTaP-HepB-IPV (Pediarix™) vaccine along with other required vaccines at birth, two, six months of age; Group B received the monovalent hepatitis B vaccine (Engerix-B) at birth, the DTaP-HepB-IPV (Pediarix™) vaccine with other vaccines at two, four and six months. Children will be evaluated for post-vaccination adverse events. Blood will be collected and immunogenicity evaluated by standardized humoral immunologic assays. The main outcome measures are to assess immune responses to each vaccine antigen over time, antibodies to pertussis (PT, FHA, PRN), diphtheria, tetanus, haemophilus influenzae type b (Hib), polio (Types 1, 2, 3) and hepatitis B (HbsAg). The secondary outcome measures are to assess vaccine safety, systemic and local immediate reactions.


Recruitment information / eligibility

Status Completed
Enrollment 5
Est. completion date August 2006
Est. primary completion date August 2006
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group N/A to 5 Days
Eligibility Inclusion Criteria:

Prenatal Inclusion Criteria

- Generally healthy, pregnant mother

- Mother will deliver at a Kaiser Permanente Medical Center participating in the study

- Ability of the parent(s) to understand and comply with the requirements of the protocol

- Signed informed consent by parent(s)

Birth Inclusion Criteria

- Healthy newborn 0 to 5 days of age

- Gestational age greater than or equal to 37 weeks to less than or equal to 42 weeks and birth weight greater than 2500 grams

- Signed informed consent obtained

- Mother continues to be eligible by prenatal screening criteria

- Newborn will receive future well child care at a Kaiser Permanente study clinic

- After reviewing with parent(s) the study procedures and informed consent, parent wishes to continue in the study

Exclusion Criteria:

Prenatal Exclusion Criteria

- Mother positive for hepatitis B surface antigen (HBsAg) or whose antigen status is unknown

- Mother positive for human immunodeficiency virus (HIV) or whose antigen status is unknown

- Mother positive for rapid plasma reagin (RPR) (syphilis) or whose antigen status is unknown

- Mother or immediate family member has impaired immunologic function

- Mother is expected to take immune suppressant medications during the last trimester of pregnancy

- Mother is expected to receive blood, blood products or immunoglobulin preparation (including hepatitis B immune globulin [HBIG]) during the last trimester of the pregnancy

- Mother with insulin dependent diabetes

- Mother with pre-eclampsia, eclampsia or abruptio placentae

- Pregnancy associated with known congenital defects

- Mother participating in another study with a non-Food and Drug Administration (FDA) approved drug, vaccine or device

- Parent(s)/guardian cannot be contacted by telephone

- Parent(s)/guardian will not continue well child care at a Kaiser Permanente study clinic

- Mother who is requesting that cord blood be retained for stem cell preservation

- Other maternal conditions that, in the opinion of the investigator, would interfere with the study

Birth Exclusion Criteria

- Current receipt of antibiotics for suspected infection in mother or newborn (based on presence of maternal fever greater than or equal to 38.0 degrees Celsius or prolonged rupture of membranes greater than or equal to 18 hours)

- Rectal temperature greater than or equal to 38.0 degrees Celsius

- Newborn receiving resuscitation [including intubation, mechanical ventilation or intravenous (IV) medication] at birth

- Suspected medical, congenital, developmental or surgical disease, including immunodeficiency, neurology disorder or seizure disorder, severe congenital anomalies or multi-organ dysfunction

- Prior receipt of hepatitis B vaccine or any other vaccine

- Received or plans to receive any immunosuppressant medication

- Receipt of blood products or immunoglobulin [including Hepatitis B Immune Globulin (HBIG)]

- Clinically significant findings on review of medical history and physical exam determined by the investigator or sub-investigator to be sufficient for exclusion

- Mother of newborn with insulin dependent diabetes

- Mother of newborn with pre-eclampsia, eclampsia or abruptio placentae

- Mother of newborn positive for HBsAG, HIV or RPR (syphilis) or whose antigen status is unknown

- Impaired immunologic function in newborn or family member

- Any condition determined by the investigator that would interfere with the evaluation of the vaccine or be a potential health risk to the subject

- Newborn is participating in another research study or has received a non-FDA approved drug or vaccine (excluding formula preparations) prior to study entry

- Parent(s)/guardian who are unable to be contacted by telephone

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Biological:
DTaP-Hep B-IPV Vaccine
U.S. licensed 13-Dec-2002. Dosage equal to 0.5 mL administered intramuscularly. Combination vaccine.
Monovalent Hep B Vaccine
U.S. licensed monovalent hepatitis B vaccine; each 0.5 mL dose contains 10 mcg of hepatitis B surface antigen absorbed on 0.25 mg aluminum hydroxide. The vaccine is given to infants as a 0.5 mL dose intramuscularly.
Drug:
Placebo
Commercially prepared normal saline. The dose will be 0.5 mL administered intramuscularly.

Locations

Country Name City State
United States UCLA Center For Vaccine Research Torrance California

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To assess the immune responses to each vaccine antigen over time, antibodies to pertussis (PT, FHA, PRN), diphtheria, tetanus, Hib, polio (Types 1, 2, 3) and hepatitis B (HbsAg) will be evaluated. Day 0-5, Day 53-70, Day 113-130, Day 173-190, and Visit 4 + (28-42 days). No
Secondary To assess vaccine safety, systemic and local immediate reactions. 30 mins after each immunization; 7 days following each vaccination; contacted 2-3 and 8 days following each vaccination to collect AE information; SAEs will be collected throughout study participation. Yes
See also
  Status Clinical Trial Phase
Completed NCT01182311 - Duration of Long-term Immunity After Hepatitis B Virus Immunization
Completed NCT04971928 - Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment Phase 1
Completed NCT03285620 - A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Participants Phase 1
Completed NCT01884415 - Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis Phase 3
Recruiting NCT05404919 - Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates Phase 2
Completed NCT02153320 - Study to Evaluate the Persistence of the Cellular and Humoral Immune Response Following Vaccinations With GlaxoSmithKline (GSK) Biologicals' Candidate Vaccines Containing HBsAg and Different Adjuvants in Healthy Adult Volunteers Phase 1
Completed NCT00352963 - Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age). Phase 3
Completed NCT03567382 - Arresting Vertical Transmission of Hepatitis B Virus Phase 4
Not yet recruiting NCT04056728 - A Phase IV Study to Assess the Safety of EupentaTM Inj Phase 4
Not yet recruiting NCT03604016 - Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver Phase 4
Completed NCT00753649 - Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants Phase 4
Recruiting NCT03027258 - Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome N/A
Completed NCT02540538 - Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders Phase 1
Terminated NCT02604199 - A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection Phase 2
Completed NCT02421666 - A Comparative Trial of Improving Care for Underserved Asian Americans Infected With HBV N/A
Completed NCT02169674 - Hepatitis B Booster Study in Adolescence Phase 4
Completed NCT01917357 - A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject Phase 3
Completed NCT01732354 - Study for Consolidation Period of Chronic Hepatitis B
Completed NCT01368497 - Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection Phase 3
Recruiting NCT01462981 - Cohort of Hepatitis B Research of Amsterdam N/A